EGFR and non-small cell lung carcinoma: They retrospectively analyzed the clinical data of 17 patients with EGFR-mutated stage IA-IIIB NSCLC who received neoadjuvant osimertinib treatment for 1–3 months followed by surgical resection and found an ORR of 88.2%.